Which has better valuation & earnings, KYNB or NXTC?

Kyntra Bio has higher revenue and earnings than NextCure. NextCure is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kyntra Bio $6.44M 4.41 $183.45M $40.46 0.17 NextCure N/A N/A -$55.84M -$17.19 N/A

Is KYNB or NXTC more profitable?

Kyntra Bio has a net margin of 2,199.13% compared to NextCure's net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat NextCure's return on equity. Company Net Margins Return on Equity Return on Assets Kyntra Bio 2,199.13% N/A -36.71% NextCure N/A -186.96% -124.62%

Do analysts rate NXTC or AIXC?

NextCure currently has a consensus target price of $23.00, suggesting a potential upside of 1,253.74%. Given NextCure's stronger consensus rating and higher probable upside, equities analysts plainly believe NextCure is more favorable than Qualigen Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NextCure 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, NXTC or AIXC?

Qualigen Therapeutics is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NextCure N/A N/A -$55.84M -$17.19 N/A Qualigen Therapeutics N/A N/A -$16.97M -$6.47 N/A

Is NXTC or AIXC more profitable?

NextCure's return on equity of -186.96% beat Qualigen Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets NextCure N/A -186.96% -124.62% Qualigen Therapeutics N/A -771.52% -79.52%

Do analysts prefer NXTC or LITS?

NextCure currently has a consensus target price of $23.00, indicating a potential upside of 1,253.74%. Given NextCure's stronger consensus rating and higher possible upside, equities research analysts clearly believe NextCure is more favorable than Lite Strategy. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NextCure 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Lite Strategy 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is NXTC or LITS more profitable?

Lite Strategy's return on equity of -90.81% beat NextCure's return on equity. Company Net Margins Return on Equity Return on Assets NextCure N/A -186.96% -124.62% Lite Strategy N/A -90.81% -89.33%

Do analysts rate TXMD or NXTC?

NextCure has a consensus price target of $23.00, indicating a potential upside of 1,253.74%. Given NextCure's stronger consensus rating and higher probable upside, analysts plainly believe NextCure is more favorable than TherapeuticsMD. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 NextCure 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Is TXMD or NXTC more profitable?

TherapeuticsMD has a net margin of 5.34% compared to NextCure's net margin of 0.00%. TherapeuticsMD's return on equity of 0.32% beat NextCure's return on equity. Company Net Margins Return on Equity Return on Assets TherapeuticsMD 5.34% 0.32% 0.23% NextCure N/A -186.96% -124.62%

Which has higher valuation & earnings, SKYE or NXTC?

Skye Bioscience is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Skye Bioscience N/A N/A -$55.92M -$1.44 N/A NextCure N/A N/A -$55.84M -$17.19 N/A

Is SKYE or NXTC more profitable?

NextCure's return on equity of -186.96% beat Skye Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Skye Bioscience N/A -217.27% -162.39% NextCure N/A -186.96% -124.62%

NextCure (NXTC) Competitors

$1.70 -0.07 (-4.01%)

As of 03:27 PM Eastern

Compare

NXTC vs. KYNB, AIXC, LITS, TXMD, and SKYE

Should you buy NextCure stock or one of its competitors? MarketBeat compares NextCure with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NextCure include Kyntra Bio (KYNB), Qualigen Therapeutics (AIXC), Lite Strategy (LITS), TherapeuticsMD (TXMD), and Skye Bioscience (SKYE). These companies are all part of the "pharmaceutical products" industry.

How does NextCure compare to Kyntra Bio?

Kyntra Bio (NASDAQ:KYNB) and NextCure (NASDAQ:NXTC) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, media sentiment, valuation and analyst recommendations.

Kyntra Bio has higher revenue and earnings than NextCure. NextCure is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyntra Bio	$6.44M	4.41	$183.45M	$40.46	0.17
NextCure	N/A	N/A	-$55.84M	-$17.19	N/A

In the previous week, Kyntra Bio's average media sentiment score of 0.00 equaled NextCure'saverage media sentiment score.

Company	Overall Sentiment
Kyntra Bio	Neutral
NextCure	Neutral

Kyntra Bio has a beta of 1.01, indicating that its stock price is 1% more volatile than the broader market. Comparatively, NextCure has a beta of 1.3, indicating that its stock price is 30% more volatile than the broader market.

72.7% of Kyntra Bio shares are owned by institutional investors. Comparatively, 42.7% of NextCure shares are owned by institutional investors. 4.2% of Kyntra Bio shares are owned by company insiders. Comparatively, 11.9% of NextCure shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Kyntra Bio has a net margin of 2,199.13% compared to NextCure's net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat NextCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyntra Bio	2,199.13%	N/A	-36.71%
NextCure	N/A	-186.96%	-124.62%

Kyntra Bio currently has a consensus price target of $30.00, suggesting a potential upside of 328.27%. NextCure has a consensus price target of $23.00, suggesting a potential upside of 1,253.74%. Given NextCure's higher probable upside, analysts clearly believe NextCure is more favorable than Kyntra Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
NextCure	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Kyntra Bio beats NextCure on 10 of the 14 factors compared between the two stocks.

How does NextCure compare to Qualigen Therapeutics?

NextCure (NASDAQ:NXTC) and Qualigen Therapeutics (NASDAQ:AIXC) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Qualigen Therapeutics is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NextCure	N/A	N/A	-$55.84M	-$17.19	N/A
Qualigen Therapeutics	N/A	N/A	-$16.97M	-$6.47	N/A

42.7% of NextCure shares are held by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are held by institutional investors. 11.9% of NextCure shares are held by insiders. Comparatively, 1.2% of Qualigen Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

NextCure's return on equity of -186.96% beat Qualigen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NextCure	N/A	-186.96%	-124.62%
Qualigen Therapeutics	N/A	-771.52%	-79.52%

In the previous week, Qualigen Therapeutics had 2 more articles in the media than NextCure. MarketBeat recorded 2 mentions for Qualigen Therapeutics and 0 mentions for NextCure. NextCure's average media sentiment score of 0.00 equaled Qualigen Therapeutics'average media sentiment score.

Company	Overall Sentiment
NextCure	Neutral
Qualigen Therapeutics	Neutral

NextCure has a beta of 1.3, suggesting that its share price is 30% more volatile than the broader market. Comparatively, Qualigen Therapeutics has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market.

NextCure currently has a consensus target price of $23.00, suggesting a potential upside of 1,253.74%. Given NextCure's stronger consensus rating and higher probable upside, equities analysts plainly believe NextCure is more favorable than Qualigen Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NextCure	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

NextCure beats Qualigen Therapeutics on 8 of the 12 factors compared between the two stocks.

How does NextCure compare to Lite Strategy?

NextCure (NASDAQ:NXTC) and Lite Strategy (NASDAQ:LITS) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends, media sentiment and institutional ownership.

42.7% of NextCure shares are owned by institutional investors. Comparatively, 52.4% of Lite Strategy shares are owned by institutional investors. 11.9% of NextCure shares are owned by company insiders. Comparatively, 1.6% of Lite Strategy shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Lite Strategy has higher revenue and earnings than NextCure. Lite Strategy is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NextCure	N/A	N/A	-$55.84M	-$17.19	N/A
Lite Strategy	$65.30M	0.42	-$15.94M	-$1.60	N/A

NextCure currently has a consensus target price of $23.00, indicating a potential upside of 1,253.74%. Given NextCure's stronger consensus rating and higher possible upside, equities research analysts clearly believe NextCure is more favorable than Lite Strategy.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NextCure	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Lite Strategy	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

NextCure has a beta of 1.3, indicating that its share price is 30% more volatile than the broader market. Comparatively, Lite Strategy has a beta of 0.21, indicating that its share price is 79% less volatile than the broader market.

In the previous week, Lite Strategy had 4 more articles in the media than NextCure. MarketBeat recorded 4 mentions for Lite Strategy and 0 mentions for NextCure. Lite Strategy's average media sentiment score of 0.57 beat NextCure's score of 0.00 indicating that Lite Strategy is being referred to more favorably in the news media.

Company	Overall Sentiment
NextCure	Neutral
Lite Strategy	Positive

Lite Strategy's return on equity of -90.81% beat NextCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NextCure	N/A	-186.96%	-124.62%
Lite Strategy	N/A	-90.81%	-89.33%

Summary

Lite Strategy beats NextCure on 8 of the 14 factors compared between the two stocks.

How does NextCure compare to TherapeuticsMD?

TherapeuticsMD (NASDAQ:TXMD) and NextCure (NASDAQ:NXTC) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and valuation.

30.7% of TherapeuticsMD shares are owned by institutional investors. Comparatively, 42.7% of NextCure shares are owned by institutional investors. 1.7% of TherapeuticsMD shares are owned by insiders. Comparatively, 11.9% of NextCure shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

TherapeuticsMD has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market. Comparatively, NextCure has a beta of 1.3, meaning that its stock price is 30% more volatile than the broader market.

In the previous week, TherapeuticsMD's average media sentiment score of 0.00 equaled NextCure'saverage media sentiment score.

Company	Overall Sentiment
TherapeuticsMD	Neutral
NextCure	Neutral

NextCure has a consensus price target of $23.00, indicating a potential upside of 1,253.74%. Given NextCure's stronger consensus rating and higher probable upside, analysts plainly believe NextCure is more favorable than TherapeuticsMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NextCure	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

TherapeuticsMD has higher revenue and earnings than NextCure. NextCure is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TherapeuticsMD	$3.02M	8.01	-$570K	$0.06	34.83
NextCure	N/A	N/A	-$55.84M	-$17.19	N/A

TherapeuticsMD has a net margin of 5.34% compared to NextCure's net margin of 0.00%. TherapeuticsMD's return on equity of 0.32% beat NextCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TherapeuticsMD	5.34%	0.32%	0.23%
NextCure	N/A	-186.96%	-124.62%

Summary

TherapeuticsMD beats NextCure on 7 of the 13 factors compared between the two stocks.

How does NextCure compare to Skye Bioscience?

Skye Bioscience (NASDAQ:SKYE) and NextCure (NASDAQ:NXTC) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability.

Skye Bioscience currently has a consensus price target of $8.50, indicating a potential upside of 1,119.51%. NextCure has a consensus price target of $23.00, indicating a potential upside of 1,253.74%. Given NextCure's higher probable upside, analysts clearly believe NextCure is more favorable than Skye Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Skye Bioscience	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50
NextCure	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Skye Bioscience has a beta of 2.95, meaning that its share price is 195% more volatile than the broader market. Comparatively, NextCure has a beta of 1.3, meaning that its share price is 30% more volatile than the broader market.

Skye Bioscience is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Skye Bioscience	N/A	N/A	-$55.92M	-$1.44	N/A
NextCure	N/A	N/A	-$55.84M	-$17.19	N/A

NextCure's return on equity of -186.96% beat Skye Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Skye Bioscience	N/A	-217.27%	-162.39%
NextCure	N/A	-186.96%	-124.62%

21.1% of Skye Bioscience shares are owned by institutional investors. Comparatively, 42.7% of NextCure shares are owned by institutional investors. 6.2% of Skye Bioscience shares are owned by company insiders. Comparatively, 11.9% of NextCure shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Skye Bioscience's average media sentiment score of 0.00 equaled NextCure'saverage media sentiment score.

Company	Overall Sentiment
Skye Bioscience	Neutral
NextCure	Neutral

Summary

NextCure beats Skye Bioscience on 8 of the 12 factors compared between the two stocks.

Get NextCure News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NXTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NXTC vs. The Competition

Export

Metric	NextCure	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.13M	$3.55B	$6.67B	$12.22B
Dividend Yield	N/A	2.28%	2.68%	5.89%
P/E Ratio	-0.10	21.23	25.73	24.02
Price / Sales	N/A	330.17	588.41	124.95
Price / Cash	N/A	130.96	45.29	53.76
Price / Book	0.17	7.99	10.51	6.33
Net Income	-$55.84M	$23.91M	$3.57B	$337.11M
7 Day Performance	-15.89%	1.55%	0.87%	-1.12%
1 Month Performance	-78.30%	1.87%	0.70%	0.46%
1 Year Performance	-69.62%	56.86%	30.92%	29.16%

NextCure Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NXTC NextCure	2.3239 of 5 stars	$1.70 -4.0%	$23.00 +1,253.7%	-68.3%	$6.13M	N/A	N/A	90
KYNB Kyntra Bio	2.7144 of 5 stars	$6.91 +0.6%	$30.00 +334.2%	N/A	$27.81M	$6.44M	N/A	570	News Coverage Gap Up
AIXC Qualigen Therapeutics	0.1494 of 5 stars	$1.49 +8.8%	N/A	N/A	$27.72M	N/A	N/A	50	High Trading Volume
LITS Lite Strategy	0.9854 of 5 stars	$0.92 +14.9%	N/A	N/A	$27.24M	$65.30M	N/A	100	High Trading Volume
TXMD TherapeuticsMD	0.7946 of 5 stars	$2.29 +0.4%	N/A	+70.3%	$26.39M	$3.02M	N/A	420	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NXTC) was last updated on 6/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NextCure (NXTC) Competitors

NXTC vs. KYNB, AIXC, LITS, TXMD, and SKYE

How does NextCure compare to Kyntra Bio?

Summary

How does NextCure compare to Qualigen Therapeutics?

Summary

How does NextCure compare to Lite Strategy?

Summary

How does NextCure compare to TherapeuticsMD?

Summary

How does NextCure compare to Skye Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NXTC vs. The Competition

NextCure Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NextCure (NXTC) Competitors

NXTC vs. KYNB, AIXC, LITS, TXMD, and SKYE

How does NextCure compare to Kyntra Bio?

Which has better valuation & earnings, KYNB or NXTC?

Does the media refer more to KYNB or NXTC?

Which has more volatility & risk, KYNB or NXTC?

Do institutionals and insiders have more ownership in KYNB or NXTC?

Is KYNB or NXTC more profitable?

Do analysts recommend KYNB or NXTC?

Summary

How does NextCure compare to Qualigen Therapeutics?

Which has better earnings and valuation, NXTC or AIXC?

Do insiders & institutionals hold more shares of NXTC or AIXC?

Is NXTC or AIXC more profitable?

Does the media refer more to NXTC or AIXC?

Which has more volatility & risk, NXTC or AIXC?

Do analysts rate NXTC or AIXC?

Summary

How does NextCure compare to Lite Strategy?

Do institutionals and insiders believe in NXTC or LITS?

Which has higher valuation and earnings, NXTC or LITS?

Do analysts prefer NXTC or LITS?

Which has more risk & volatility, NXTC or LITS?

Does the media favor NXTC or LITS?

Is NXTC or LITS more profitable?

Summary

How does NextCure compare to TherapeuticsMD?

Do insiders and institutionals believe in TXMD or NXTC?

Which has more volatility and risk, TXMD or NXTC?

Does the media prefer TXMD or NXTC?

Do analysts rate TXMD or NXTC?

Which has preferable earnings & valuation, TXMD or NXTC?

Is TXMD or NXTC more profitable?

Summary

How does NextCure compare to Skye Bioscience?

Do analysts rate SKYE or NXTC?

Which has more volatility & risk, SKYE or NXTC?

Which has higher valuation & earnings, SKYE or NXTC?

Is SKYE or NXTC more profitable?

Do insiders & institutionals believe in SKYE or NXTC?

Does the media prefer SKYE or NXTC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NXTC vs. The Competition

NextCure Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools